Gi-Young Sohn
Chief Executive Officer en ENZYCHEM LIFESCIENCES CORPORATION .
Fortuna: 6 M $ al 30/04/2024
Perfil
Gi-Young Sohn is currently the Chief Executive Officer & Director at ENZYCHEM LIFESCIENCES Corp.
since 2012.
He is also the Chairman at Bridget Lifesciences Corp.
since 2003.
Mr. Sohn has an undergraduate and graduate degree from Korea University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 07/05/2024 | 4 069 430 ( 4.78% ) | 6 M $ | 30/04/2024 |
Cargos activos de Gi-Young Sohn
| Empresas | Cargo | Inicio |
|---|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Chief Executive Officer | 01/06/2012 |
Bridget Lifesciences Corp.
 Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Chairman | 01/01/2003 |
Formación de Gi-Young Sohn.
| Korea University | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Health Technology |
| Empresas privadas | 1 |
|---|---|
Bridget Lifesciences Corp.
Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Finance |
- Bolsa de valores
- Insiders
- Gi-Young Sohn
